This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Alzheimer's Disease
  • /
  • Tricaprilin Phase 3 AD Study
Clinical trial

Tricaprilin Phase 3 AD Study

Read time: 1 mins
Last updated:11th Apr 2023
Identifier: NCT05809908
Tricaprilin Phase 3 AD Study ID: NCT05809908

Sponsor: Cerecin
Information provided by: Cerecin (Responsible Party)
Last Update Posted: 2023-04-12

Brief Summary:

The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, activities of daily living, resource utilisation, safety and tolerability, in subjects with mild to moderately severe probable AD.

This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.

Official Title:
A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease

Intervention / Treatment:
- Drug: Tricaprilin
- Drug: Placebo

Category Value
Study Start (Estimated) 2024-01
Primary Completion (Estimated) 2026-01
Study Completion (Estimated) 2027-01
Enrollment (Estimated) 535
Study Type Interventional
Phase Phase 3
Other Study ID Numbers

View full details